

Supplementary Table 7. Evidence contribution matrices for the primary histological outcomes and liver fat content outcomes

Note: Rows represented network treatment comparisons, whereas columns represented direct comparisons in the evidence network. This analysis was used to clarify the extent to which active-versus-active estimates were informed by direct evidence or indirectly through the placebo. For example, in the comparison between d-(R)-pioglitazone and FGF19 analogue on fibrosis improvement without worsening of steatohepatitis, the estimate was mainly derived from the direct comparisons of d-(R)-pioglitazone versus placebo and FGF19 analogue versus placebo, each contributing approximately 50% to the network estimate. ACC, acetyl-coenzyme A carboxylase; FGF, fibroblast growth factor; FXR, farnesoid X receptor; GLP-1, glucagon-like peptide-1; GCG, glucagon; GIP, glucose-dependent insulinotropic polypeptide; PPAR, peroxisome proliferator-activated receptor; THR, thyroid hormone receptor; RA, receptor agonist.

Supplementary Table 7.1 Evidence contribution matrix for fibrosis improvement without worsening of steatohepatitis

Comparisons	d-(R)-Pioglitazone: Placebo	FGF19 analogue: Placebo	FGF21 analogue: Placebo	FXR agonist: Placebo	GLP-1 RA: Placebo	GLP-1/GCG dual RA: Placebo	GLP-1/GIP dual RA: Placebo	Placebo: PPAR agonist	Placebo: THR- β agonist
d-(R)-Pioglitazone: FGF19 analogue	50.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
d-(R)-Pioglitazone: FGF21 analogue	50.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
d-(R)-Pioglitazone: FXR agonist	50.0%	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%
d-(R)-Pioglitazone: GLP-1 RA	50.0%	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%
d-(R)-Pioglitazone: GLP-1/GCG dual RA	50.0%	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%
d-(R)-Pioglitazone: GLP-1/GIP dual RA	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%
d-(R)-Pioglitazone: Placebo	100.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
d-(R)-Pioglitazone: PPAR agonist	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%

d-(R)-Pioglitazone: THR-β agonist	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%
FGF19 analogue: FGF21 analogue	0.0%	50.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
FGF19 analogue: FXR agonist	0.0%	50.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%
FGF19 analogue: GLP-1 RA	0.0%	50.0%	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%
FGF19 analogue: GLP-1/GCG dual RA	0.0%	50.0%	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%
FGF19 analogue: GLP-1/GIP dual RA	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%
FGF19 analogue: Placebo	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
FGF19 analogue: PPAR agonist	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%
FGF19 analogue: THR-β agonist	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%
FGF21 analogue: FXR agonist	0.0%	0.0%	50.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%
FGF21 analogue: GLP-1 RA	0.0%	0.0%	50.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%
FGF21 analogue: GLP-1/GCG dual RA	0.0%	0.0%	50.0%	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%
FGF21 analogue: GLP-1/GIP dual RA	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%
FGF21 analogue: Placebo	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
FGF21 analogue: PPAR agonist	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%
FGF21 analogue: THR-β agonist	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%
FXR agonist: GLP-1 RA	0.0%	0.0%	0.0%	50.0%	50.0%	0.0%	0.0%	0.0%	0.0%

FXR agonist: GLP-1/GCG dual RA	0.0%	0.0%	0.0%	50.0%	0.0%	50.0%	0.0%	0.0%	0.0%
FXR agonist: GLP-1/GIP dual RA	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%	50.0%	0.0%	0.0%
FXR agonist: Placebo	0.0%	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	0.0%
FXR agonist: PPAR agonist	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	50.0%	0.0%
FXR agonist: THR- β agonist	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	50.0%
GLP-1 RA: GLP-1/GCG dual RA	0.0%	0.0%	0.0%	0.0%	50.0%	50.0%	0.0%	0.0%	0.0%
GLP-1 RA: GLP-1/GIP dual RA	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%	50.0%	0.0%	0.0%
GLP-1 RA: Placebo	0.0%	0.0%	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%
GLP-1 RA: PPAR agonist	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%	50.0%	0.0%
GLP-1 RA: THR- β agonist	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	50.0%
GLP-1/GCG dual RA: GLP-1/GIP dual RA	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%	50.0%	0.0%	0.0%
GLP-1/GCG dual RA: Placebo	0.0%	0.0%	0.0%	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%
GLP-1/GCG dual RA: PPAR agonist	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%	50.0%	0.0%
GLP-1/GCG dual RA: THR- β agonist	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%	50.0%
GLP-1/GIP dual RA: Placebo	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	100.0%	0.0%	0.0%
GLP-1/GIP dual RA: PPAR agonist	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%	50.0%	0.0%

GLP-1/GIP dual RA: THR- β agonist	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%	50.0%
Placebo: PPAR agonist	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	100.0%	0.0%
Placebo: THR- β agonist	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	100.0%
PPAR agonist: THR- β agonist	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%	50.0%

Supplementary Table 7.2 Evidence contribution matrix for steatohepatitis resolution without worsening of fibrosis

Comparisons	d-(R)-Pioglitazone: Placebo	FGF19 analogue: Placebo	FGF21 analogue: Placebo	FXR agonist: Placebo	GLP-1 RA: Placebo	GLP-1/GC G dual RA: Placebo	GLP-1/GI P dual RA: Placebo	Placebo: PPAR agonist	Placebo: THR- β agonist
d-(R)-Pioglitazone: FGF19 analogue	50.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
d-(R)-Pioglitazone: FGF21 analogue	50.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
d-(R)-Pioglitazone: FXR agonist	50.0%	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%
d-(R)-Pioglitazone: GLP-1 RA	50.0%	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%
d-(R)-Pioglitazone: GLP-1/GCG dual RA	50.0%	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%
d-(R)-Pioglitazone: GLP-1/GIP dual RA	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%
d-(R)-Pioglitazone: Placebo	100.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
d-(R)-Pioglitazone: PPAR agonist	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%
d-(R)-Pioglitazone: THR- β agonist	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%
FGF19 analogue: FGF21 analogue	0.0%	50.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
FGF19 analogue: FXR agonist	0.0%	50.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%
FGF19 analogue: GLP-1 RA	0.0%	50.0%	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%
FGF19 analogue: GLP-1/GCG dual RA	0.0%	50.0%	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%

FGF19 analogue: GLP-1/GIP dual RA	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%
FGF19 analogue: Placebo	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
FGF19 analogue: PPAR agonist	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%
FGF19 analogue: THR- β agonist	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%
FGF21 analogue: FXR agonist	0.0%	0.0%	50.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%
FGF21 analogue: GLP-1 RA	0.0%	0.0%	50.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%
FGF21 analogue: GLP-1/GCG dual RA	0.0%	0.0%	50.0%	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%
FGF21 analogue: GLP-1/GIP dual RA	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%
FGF21 analogue: Placebo	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
FGF21 analogue: PPAR agonist	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%
FGF21 analogue: THR- β agonist	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%
FXR agonist: GLP-1 RA	0.0%	0.0%	0.0%	50.0%	50.0%	0.0%	0.0%	0.0%	0.0%
FXR agonist: GLP-1/GCG dual RA	0.0%	0.0%	0.0%	50.0%	0.0%	50.0%	0.0%	0.0%	0.0%
FXR agonist: GLP-1/GIP dual RA	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%	50.0%	0.0%	0.0%
FXR agonist: Placebo	0.0%	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	0.0%
FXR agonist: PPAR agonist	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	50.0%	0.0%
FXR agonist: THR- β agonist	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	50.0%

GLP-1 RA: GLP-1/GCG dual RA	0.0%	0.0%	0.0%	0.0%	50.0%	50.0%	0.0%	0.0%	0.0%
GLP-1 RA: GLP-1/GIP dual RA	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%	50.0%	0.0%	0.0%
GLP-1 RA: Placebo	0.0%	0.0%	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%
GLP-1 RA: PPAR agonist	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%	50.0%	0.0%
GLP-1 RA: THR- β agonist	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	50.0%
GLP-1/GCG dual RA: GLP-1/GIP dual RA	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%	50.0%	0.0%	0.0%
GLP-1/GCG dual RA: Placebo	0.0%	0.0%	0.0%	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%
GLP-1/GCG dual RA: PPAR agonist	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%	50.0%	0.0%
GLP-1/GCG dual RA: THR- β agonist	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%	50.0%
GLP-1/GIP dual RA: Placebo	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	100.0%	0.0%	0.0%
GLP-1/GIP dual RA: PPAR agonist	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%	50.0%	0.0%
GLP-1/GIP dual RA: THR- β agonist	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%	50.0%
Placebo: PPAR agonist	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	100.0%	0.0%
Placebo: THR- β agonist	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	100.0%
PPAR agonist: THR- β agonist	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%	50.0%

Supplementary Table 7.3 Evidence contribution matrix for relative change in liver fat content

Comparisons	ACC inhibitor: Placebo	d-(R)-Pioglitazone: Placebo	FGF19 analogue: Placebo	FGF21 analogue: Placebo	FXR agonist: Placebo	GLP-1 RA: GLP-1/GC G dual RA	GLP-1 RA: Placebo	GLP-1/GC G dual RA: Placebo	GLP-1/GI P dual RA: Placebo	GLP-1/GI P/GCG triple agonist: Placebo	Placebo: PPAR agonist	Placebo: THR- β agonist
ACC inhibitor: d-(R)-Pioglitazone	50.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
ACC inhibitor: FGF19 analogue	50.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
ACC inhibitor: FGF21 analogue	50.0%	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
ACC inhibitor: FXR agonist	50.0%	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
ACC inhibitor: GLP-1 RA	42.6%	0.0%	0.0%	0.0%	0.0%	14.7%	27.9%	14.7%	0.0%	0.0%	0.0%	0.0%
ACC inhibitor: GLP-1/GC G dual RA	45.6%	0.0%	0.0%	0.0%	0.0%	8.8%	8.8%	36.8%	0.0%	0.0%	0.0%	0.0%
ACC inhibitor:	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%

GLP-1/GI P dual RA												
ACC inhibitor: GLP-1/GI P/ GCG triple agonist	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%
ACC inhibitor: Placebo	100.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
ACC inhibitor: PPAR agonist	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%
ACC inhibitor: THR- β agonist	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%
d-(R)-Piog litazone: FGF19 analogue	0.0%	50.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
d-(R)-Piog litazone: FGF21 analogue	0.0%	50.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
d-(R)-Piog litazone: FXR agonist	0.0%	50.0%	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

d-(R)-Pioglitazone: GLP-1 RA	0.0%	42.6%	0.0%	0.0%	0.0%	14.7%	27.9%	14.7%	0.0%	0.0%	0.0%	0.0%
d-(R)-Pioglitazone: GLP-1/GC G dual RA	0.0%	45.6%	0.0%	0.0%	0.0%	8.8%	8.8%	36.8%	0.0%	0.0%	0.0%	0.0%
d-(R)-Pioglitazone: GLP-1/GI P dual RA	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%
d-(R)-Pioglitazone: GLP-1/GI P/ GCG triple agonist	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%
d-(R)-Pioglitazone: Placebo	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
d-(R)-Pioglitazone: PPAR agonist	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%
d-(R)-Pioglitazone: THR- β agonist	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%
FGF19 analogue: FGF21	0.0%	0.0%	50.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

analogue												
FGF19 analogue: FXR agonist	0.0%	0.0%	50.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
FGF19 analogue: GLP-1 RA	0.0%	0.0%	42.6%	0.0%	0.0%	14.7%	27.9%	14.7%	0.0%	0.0%	0.0%	0.0%
FGF19 analogue: GLP-1/GC G dual RA	0.0%	0.0%	45.6%	0.0%	0.0%	8.8%	8.8%	36.8%	0.0%	0.0%	0.0%	0.0%
FGF19 analogue: GLP-1/GI P dual RA	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%
FGF19 analogue: GLP-1/GI P/GCG triple agonist	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%
FGF19 analogue: Placebo	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
FGF19 analogue: PPAR agonist	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%
FGF19	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%

analogue: THR- β agonist												
FGF21 analogue: FXR agonist	0.0%	0.0%	0.0%	50.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
FGF21 analogue: GLP-1 RA	0.0%	0.0%	0.0%	42.6%	0.0%	14.7%	27.9%	14.7%	0.0%	0.0%	0.0%	0.0%
FGF21 analogue: GLP-1/GC G dual RA	0.0%	0.0%	0.0%	45.6%	0.0%	8.8%	8.8%	36.8%	0.0%	0.0%	0.0%	0.0%
FGF21 analogue: GLP-1/GI P dual RA	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%
FGF21 analogue: GLP-1/GI P/GCG triple agonist	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%
FGF21 analogue: Placebo	0.0%	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
FGF21 analogue: PPAR agonist	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%

FGF21 analogue: THR- β agonist	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%
FXR agonist:G LP-1 RA	0.0%	0.0%	0.0%	0.0%	42.6%	14.7%	27.9%	14.7%	0.0%	0.0%	0.0%	0.0%
FXR agonist:G LP-1/GCG dual RA	0.0%	0.0%	0.0%	0.0%	45.6%	8.8%	8.8%	36.8%	0.0%	0.0%	0.0%	0.0%
FXR agonist:G LP-1/GIP dual RA	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%
FXR agonist:G LP-1/GIP/ GCG triple agonist	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%
FXR agonist: Placebo	0.0%	0.0%	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
FXR agonist: PPAR agonist	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%
FXR agonist: THR- β agonist	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%

GLP-1 RA: GLP-1/GC G dual RA	0.0%	0.0%	0.0%	0.0%	0.0%	70.6%	14.7%	14.7%	0.0%	0.0%	0.0%	0.0%
GLP-1 RA: GLP-1/GI P dual RA	0.0%	0.0%	0.0%	0.0%	0.0%	14.7%	27.9%	14.7%	42.6%	0.0%	0.0%	0.0%
GLP-1 RA:GLP-1 /GIP/GCG triple agonist	0.0%	0.0%	0.0%	0.0%	0.0%	14.7%	27.9%	14.7%	0.0%	42.6%	0.0%	0.0%
GLP-1 RA: Placebo	0.0%	0.0%	0.0%	0.0%	0.0%	22.1%	55.8%	22.1%	0.0%	0.0%	0.0%	0.0%
GLP-1 RA: PPAR agonist	0.0%	0.0%	0.0%	0.0%	0.0%	14.7%	27.9%	14.7%	0.0%	0.0%	42.6%	0.0%
GLP-1 RA: THR- β agonist	0.0%	0.0%	0.0%	0.0%	0.0%	14.7%	27.9%	14.7%	0.0%	0.0%	0.0%	42.6%
GLP-1/GC G dual RA: GLP-1/GI P dual RA	0.0%	0.0%	0.0%	0.0%	0.0%	8.8%	8.8%	36.8%	45.6%	0.0%	0.0%	0.0%
GLP-1/GC G dual RA:	0.0%	0.0%	0.0%	0.0%	0.0%	8.8%	8.8%	36.8%	0.0%	45.6%	0.0%	0.0%

GLP-1/GI P/ GCG triple agonist												
GLP-1/GC G dual RA: Placebo	0.0%	0.0%	0.0%	0.0%	0.0%	13.2%	13.2%	73.6%	0.0%	0.0%	0.0%	0.0%
GLP-1/GC G dual RA: PPAR agonist	0.0%	0.0%	0.0%	0.0%	0.0%	8.8%	8.8%	36.8%	0.0%	0.0%	45.6%	0.0%
GLP-1/GC G dual RA: THR- β agonist	0.0%	0.0%	0.0%	0.0%	0.0%	8.8%	8.8%	36.8%	0.0%	0.0%	0.0%	45.6%
GLP-1/GI P dual RA: GLP-1/GI P/GCG triple agonist	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%	50.0%	0.0%	0.0%
GLP-1/GI P dual RA: Placebo	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%
GLP-1/GI P dual RA: PPAR agonist	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%	50.0%	0.0%
GLP-1/GI	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%	50.0%

P dual RA: THR-β agonist												
GLP-1/GI P/GCG triple agonist: Placebo	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	100.0%	0.0%	0.0%
GLP-1/GI P/ GCG triple agonist: PPAR agonist	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%	50.0%	0.0%
GLP-1/GI P/GCG triple agonist: THR-β agonist	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%	50.0%
Placebo: PPAR agonist	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	100.0%	0.0%
Placebo: THR-β agonist	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	100.0%
PPAR agonist: THR-β agonist	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%	50.0%

Supplementary Table 7.4 Evidence contribution matrix for absolute change in liver fat content

	d-(R)-Pi oglitazon e: Placebo	FGF19 analogue : Placebo	FGF21 analogue : Placebo	FXR agonist: Placebo	GLP-1 RA: GLP-1 RA+AC C inhibitor	GLP-1 RA: GLP-1 RA+FX R agonist	GLP-1 RA: GLP-1 RA+AC C inhibitor +FXR agonist	GLP-1 RA: Placebo	GLP-1/G CG dual RA: Placebo	GLP-1 RA+AC C inhibitor: GLP-1 RA+FX R agonist	GLP-1 RA+AC C inhibitor: GLP-1 RA+AC C inhibitor +FXR agonist	GLP-1 RA+FX R agonist	Placebo: PPAR agonist	Placebo: THR- β agonist
d-(R)-Pi oglitazon e: FGF19 analogue	50.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
d-(R)-Pi oglitazon e: FGF21 analogue	50.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
d-(R)-Pi oglitazon e: FXR agonist	50.0%	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
d-(R)-Pi oglitazon e: GLP-1 RA	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

d-(R)-Pi oglitazone: GLP-1/G CG dual RA	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%
d-(R)-Pi oglitazone: GLP-1R A+ACC inhibitor	29.2%	0.0%	0.0%	0.0%	16.8%	6.3%	6.1%	29.2%	0.0%	6.3%	6.1%	0.0%	0.0%	0.0%
d-(R)-Pi oglitazone: GLP-1R A+FXR agonist	29.2%	0.0%	0.0%	0.0%	6.3%	16.8%	6.1%	29.2%	0.0%	6.3%	0.0%	6.1%	0.0%	0.0%
d-(R)-Pi oglitazone: GLP-1 RA+ACC inhibitor +FXR agonist	29.1%	0.0%	0.0%	0.0%	6.3%	6.3%	16.5%	29.1%	0.0%	0.0%	6.3%	6.3%	0.0%	0.0%
d-(R)-Pi oglitazone: Placebo	100.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
d-(R)-Pi	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%

oglitazone: PPAR agonist														
d-(R)-Pioglitazone: THR- β agonist	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%
FGF19 analogue : FGF21 analogue	0.0%	50.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
FGF19 analogue : FXR agonist	0.0%	50.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
FGF19 analogue : GLP-1 RA	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
FGF19 analogue : GLP-1/GCG dual RA	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%
FGF19 analogue : GLP-1RA+ACC	0.0%	29.2%	0.0%	0.0%	16.8%	6.3%	6.1%	29.2%	0.0%	6.3%	6.1%	0.0%	0.0%	0.0%

inhibitor														
FGF19 analogue : GLP-1R A+FXR agonist	0.0%	29.2%	0.0%	0.0%	6.3%	16.8%	6.1%	29.2%	0.0%	6.3%	0.0%	6.1%	0.0%	0.0%
FGF19 analogue : GLP-1 RA+AC C inhibitor +FXR agonist	0.0%	29.1%	0.0%	0.0%	6.3%	6.3%	16.5%	29.1%	0.0%	0.0%	6.3%	6.3%	0.0%	0.0%
FGF19 analogue : Placebo	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
FGF19 analogue : PPAR agonist	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%
FGF19 analogue : THR- β agonist	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%
FGF21 analogue : FXR agonist	0.0%	0.0%	50.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
FGF21	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

analogue : GLP-1 RA														
FGF21 analogue : GLP-1/G CG dual RA	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%
FGF21 analogue : GLP-1R A+ACC inhibitor	0.0%	0.0%	29.2%	0.0%	16.8%	6.3%	6.1%	29.2%	0.0%	6.3%	6.1%	0.0%	0.0%	0.0%
FGF21 analogue : GLP-1R A+FXR agonist	0.0%	0.0%	29.2%	0.0%	6.3%	16.8%	6.1%	29.2%	0.0%	6.3%	0.0%	6.1%	0.0%	0.0%
FGF21 analogue : GLP-1 RA+AC C inhibitor +FXR agonist	0.0%	0.0%	29.1%	0.0%	6.3%	6.3%	16.5%	29.1%	0.0%	0.0%	6.3%	6.3%	0.0%	0.0%
FGF21 analogue	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

: Placebo														
FGF21 analogue : PPAR agonist	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%
FGF21 analogue : THR- β agonist	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%
FXR agonist: GLP-1 RA	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
FXR agonist: GLP-1/G CG dual RA	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%
FXR agonist: GLP-1R A+ACC inhibitor	0.0%	0.0%	0.0%	29.2%	16.8%	6.3%	6.1%	29.2%	0.0%	6.3%	6.1%	0.0%	0.0%	0.0%
FXR agonist: GLP-1R A+FXR agonist	0.0%	0.0%	0.0%	29.2%	6.3%	16.8%	6.1%	29.2%	0.0%	6.3%	0.0%	6.1%	0.0%	0.0%
FXR agonist: GLP-1	0.0%	0.0%	0.0%	29.1%	6.3%	6.3%	16.5%	29.1%	0.0%	0.0%	6.3%	6.3%	0.0%	0.0%

RA+ACC inhibitor +FXR agonist														
FXR agonist: Placebo	0.0%	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
FXR agonist: PPAR agonist	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%
FXR agonist: THR- β agonist	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%
GLP-1 RA: GLP-1/G CG dual RA	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%
GLP-1 RA: GLP-1R A+ACC inhibitor	0.0%	0.0%	0.0%	0.0%	50.3%	12.6%	12.2%	0.0%	0.0%	12.6%	12.2%	0.0%	0.0%	0.0%
GLP-1 RA: GLP-1R A+FXR agonist	0.0%	0.0%	0.0%	0.0%	12.6%	50.3%	12.2%	0.0%	0.0%	12.6%	0.0%	12.2%	0.0%	0.0%

GLP-1 RA: GLP-1 RA+ACC inhibitor +FXR agonist	0.0%	0.0%	0.0%	0.0%	12.6%	12.6%	49.5%	0.0%	0.0%	0.0%	12.6%	12.6%	0.0%	0.0%
GLP-1 RA: Placebo	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
GLP-1 RA: PPAR agonist	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%
GLP-1 RA: THR- β agonist	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%
GLP-1/G CG dual RA: GLP-1R A+ACC inhibitor	0.0%	0.0%	0.0%	0.0%	16.8%	6.3%	6.1%	29.2%	29.2%	6.3%	6.1%	0.0%	0.0%	0.0%
GLP-1/G CG dual RA: GLP-1R A+FXR agonist	0.0%	0.0%	0.0%	0.0%	6.3%	16.8%	6.1%	29.2%	29.2%	6.3%	0.0%	6.1%	0.0%	0.0%

GLP-1/G CG dual RA: GLP-1 RA+ACC inhibitor +FXR agonist	0.0%	0.0%	0.0%	0.0%	6.3%	6.3%	16.5%	29.1%	29.1%	0.0%	6.3%	6.3%	0.0%	0.0%
GLP-1/G CG dual RA: Placebo	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	0.0%
GLP-1/G CG dual RA: PPAR agonist	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	50.0%	0.0%
GLP-1/G CG dual RA: THR- β agonist	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	50.0%
GLP-1R A+ACC inhibitor: GLP-1R A+FXR agonist	0.0%	0.0%	0.0%	0.0%	12.5%	12.5%	0.0%	0.0%	0.0%	50.5%	12.2%	12.2%	0.0%	0.0%
GLP-1R A+ACC	0.0%	0.0%	0.0%	0.0%	12.5%	0.0%	12.5%	0.0%	0.0%	12.6%	49.7%	12.6%	0.0%	0.0%

inhibitor: GLP-1 RA+ACC C inhibitor +FXR agonist														
GLP-1R A+ACC inhibitor: Placebo	0.0%	0.0%	0.0%	0.0%	25.2%	8.4%	8.1%	41.7%	0.0%	8.4%	8.1%	0.0%	0.0%	0.0%
GLP-1R A+ACC inhibitor: PPAR agonist	0.0%	0.0%	0.0%	0.0%	16.8%	6.3%	6.1%	29.2%	0.0%	6.3%	6.1%	0.0%	29.2%	0.0%
GLP-1R A+ACC inhibitor: THR- β agonist	0.0%	0.0%	0.0%	0.0%	16.8%	6.3%	6.1%	29.2%	0.0%	6.3%	6.1%	0.0%	0.0%	29.2%
GLP-1R A+FXR agonist: GLP-1 RA+ACC C inhibitor +FXR agonist	0.0%	0.0%	0.0%	0.0%	0.0%	12.5%	12.5%	0.0%	0.0%	12.6%	12.6%	49.7%	0.0%	0.0%
GLP-1R	0.0%	0.0%	0.0%	0.0%	8.4%	25.2%	8.1%	41.7%	0.0%	8.4%	0.0%	8.1%	0.0%	0.0%

A+FXR agonist: Placebo														
GLP-1R A+FXR agonist: PPAR agonist	0.0%	0.0%	0.0%	0.0%	6.3%	16.8%	6.1%	29.2%	0.0%	6.3%	0.0%	6.1%	29.2%	0.0%
GLP-1R A+FXR agonist: THR- β agonist	0.0%	0.0%	0.0%	0.0%	6.3%	16.8%	6.1%	29.2%	0.0%	6.3%	0.0%	6.1%	0.0%	29.2%
GLP-1 RA+AC C inhibitor +FXR agonist: Placebo	0.0%	0.0%	0.0%	0.0%	8.4%	8.4%	24.7%	41.6%	0.0%	0.0%	8.4%	8.4%	0.0%	0.0%
GLP-1 RA+AC C inhibitor +FXR agonist: PPAR agonist	0.0%	0.0%	0.0%	0.0%	6.3%	6.3%	16.5%	29.1%	0.0%	0.0%	6.3%	6.3%	29.1%	0.0%
GLP-1 RA+AC C	0.0%	0.0%	0.0%	0.0%	6.3%	6.3%	16.5%	29.1%	0.0%	0.0%	6.3%	6.3%	0.0%	29.1%

inhibitor +FXR agonist: THR- β agonist														
Placebo: PPAR agonist	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	100.0%	0.0%
Placebo: THR- β agonist	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	100.0%
PPAR agonist: THR- β agonist	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	50.0%	50.0%